Drug intelligence / Profile preview

CIM201

Development stage: Unknown
Lead developer: CiMaas
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intradermal, Intravenous

Overview

CIM201 is an autologous dendritic cell (DC) vaccine developed by CiMaas for the treatment of breast cancer. The therapy involves the isolation of monocytes from the patient, which are then differentiated into mature dendritic cells and loaded with tumor-associated antigens to stimulate a robust T-cell mediated immune response against the tumor. By presenting these antigens to the patient's immune system, CIM201 aims to activate and expand tumor-specific T cells that can recognize and eliminate breast cancer cells. As of early 2023, the program was listed in Phase 2 clinical development.

Targets

TA-MUC1 (Tumor-associated MUC1)

Beyond the preview

Go deeper on CIM201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CIM201.

Explore the full profile